10-Q: GE HealthCare Reports Mixed Q3, Revenue Up Amid Profit Dip

GE HealthCare Technologies Inc. reported a 6% increase in Q3 revenues to $5.14 billion, but net income attributable to the company declined 5% to $446 million, impacted by cost inflation and tariffs.

Summary

• Total revenues for the three months ended September 30, 2025, increased 6% to $5,143 million (4% organic growth) compared to $4,863 million in the prior year.
• Net income attributable to GE HealthCare for Q3 2025 decreased 5% to $446 million, down from $470 million in Q3 2024.
• Diluted earnings per share (EPS) for Q3 2025 was $0.98, a decrease from $1.02 in Q3 2024.
• Operating income for Q3 2025 decreased 3% to $653 million, compared to $676 million in Q3 2024.
• For the nine months ended September 30, 2025, total revenues grew 4% to $14,927 million (3% organic growth) compared to $14,353 million in the prior year.
• Net income attributable to GE HealthCare for the nine months ended September 30, 2025, increased 18% to $1,495 million, up from $1,272 million in the prior year period.
• Diluted EPS for the nine months ended September 30, 2025, was $3.26, an increase from $2.77 in the prior year period.
• Cash from operating activities for the nine months ended September 30, 2025, decreased 10% to $937 million, down from $1,042 million in the prior year period.
• Free cash flow for the nine months ended September 30, 2025, decreased 21% to $589 million, down from $743 million in the prior year period.
• The company completed the acquisition of the remaining 50% interest in Nihon Medi-Physics Co., Ltd. (NMP) for $271 million, recognizing a $97 million gain on remeasurement of its existing interest.
• An agreement to acquire icometrix NV was announced on September 10, 2025, expected to close in Q4 2025.
• A share repurchase program of up to $1,000 million was authorized on April 30, 2025, with $200 million repurchased year-to-date.

Sentiment

Score: 5

Explanation: The sentiment is mixed. While revenue growth is positive and strategic acquisitions are being made, Q3 profitability (net income, EPS, operating income) and year-to-date free cash flow have declined. The company faces headwinds from cost inflation, tariffs, and delays in the China market stimulus program, partially offset by strong performance in specific segments and effective debt management.

Positives

• Total revenues increased 6% (4% organic) in Q3 2025 to $5,143 million, demonstrating continued top-line growth.
• Pharmaceutical Diagnostics (PDx) segment revenues grew significantly by 20% (10% organic) in Q3 2025 to $749 million, and 13% (7% organic) year-to-date, driven by the NMP acquisition and increased volume and price.
• Advanced Visualization Solutions (AVS) segment revenues increased 7% (6% organic) in Q3 2025 to $1,301 million, with Segment EBIT growing 17% to $271 million, reflecting strong U.S. market performance and cost productivity.
• Year-to-date Net income attributable to GE HealthCare increased 18% to $1,495 million, and diluted EPS increased by $0.49 to $3.26, indicating stronger performance over the longer period.
• The acquisition of the remaining 50% interest in Nihon Medi-Physics (NMP) generated a $97 million gain on remeasurement of the previously held interest, strengthening the PDx portfolio.
• The announced acquisition of icometrix NV aligns with the precision care strategy and aims to strengthen neurological care offerings.
• A $1,000 million share repurchase program was authorized, with $200 million already executed year-to-date, signaling confidence in valuation and returning capital to shareholders.
• Cash, cash equivalents, and restricted cash increased to $4,027 million as of September 30, 2025, from $2,889 million at December 31, 2024, enhancing liquidity.
• Debt optimization efforts led to a $19 million decrease in net interest and other financial charges in Q3 2025 and a $49 million decrease year-to-date.
• The company remains in compliance with all debt covenant requirements, including the maximum consolidated net leverage ratio.

Negatives

• Net income attributable to GE HealthCare decreased 5% in Q3 2025 to $446 million, and diluted EPS declined to $0.98 from $1.02 in the prior year quarter.
• Operating income decreased 3% in Q3 2025 to $653 million, and gross profit decreased by $36 million, primarily due to increased cost of products and services sold as a percentage of revenues.
• Cost of products sold increased by 380 basis points as a percentage of sales in Q3 2025, driven by cost inflation and incremental tariffs.
• Cost of services sold increased by 160 basis points as a percentage of sales in Q3 2025, due to unfavorable mix and cost inflation, including tariffs.
• Patient Care Solutions (PCS) segment revenues decreased 6% (7% organic) in Q3 2025 to $731 million, with Segment EBIT declining 67% to $27 million, primarily due to a product hold and unfavorable mix.
• Imaging Segment EBIT decreased 16% in Q3 2025 to $240 million, impacted by cost inflation and incremental tariffs.
• China region revenues decreased 3% in Q3 2025 and 2% year-to-date, attributed to slower-than-anticipated implementation of the government's 2024 stimulus program.
• Cash from operating activities decreased 10% year-to-date to $937 million, and Free cash flow decreased 21% year-to-date to $589 million.
• Non-operating benefit income decreased by $27 million in Q3 2025 and $83 million year-to-date, primarily due to lower expected returns on plan assets.
• Provision for income taxes increased by $11 million in Q3 2025, primarily due to U.S. and foreign tax law changes.

Risks

• Operating in highly competitive markets could impact market share and profitability.
• Global geopolitical and economic instability, including changes in trade and tariff policy, and international conflicts (e.g., Ukraine/Russia, Middle East), could adversely affect operations, supply chains, and financial results.
• Public health crises, epidemics, and pandemics may impact business operations and demand for products.
• Changes in third-party and government reimbursement processes, rates, and contractual relationships, including government shutdowns, could affect revenue and profitability.
• Demand for products, services, or solutions is subject to various factors, and a decline could negatively impact financial performance.
• Developments in the China market, including slower-than-anticipated implementation of stimulus programs, could continue to impact orders and revenues.
• The ability to control increases in healthcare costs and any subsequent effect on demand for products, services, or solutions poses a risk.
• Successful completion of strategic transactions, such as acquisitions, is not guaranteed and integration risks exist.
• Increasing focus on and investment in cloud, edge computing, artificial intelligence (AI), and software offerings may not yield expected returns.
• Challenges in managing the supply chain and cost-effectively securing necessary materials could disrupt operations and increase costs.
• Disruptions in operations, including manufacturing and logistics, could impact product availability and service delivery.
• Actions or inactions of third parties with whom the company partners, and the success of various collaboration, licensing, and other partnerships, are critical.
• Potential information technology, cybersecurity, or data security breaches could lead to financial losses, reputational damage, and regulatory penalties.
• Maintenance and protection of intellectual property rights, as well as successful research and development efforts, are essential for commercial success.
• The ability to attract and/or retain key personnel and qualified employees is crucial for sustained operations and growth.
• Compliance with various legal, regulatory, tax, privacy, and other laws (e.g., Foreign Corrupt Practices Act) is complex and non-compliance could result in significant penalties.
• Potential product liability claims could lead to substantial financial liabilities and reputational damage.
• The company's level of indebtedness and general ability to comply with covenants under debt instruments could affect financial flexibility.
• The ongoing legal proceedings related to contracts with the Iraqi Ministry of Health, alleging violations of the U.S. Anti-Terrorism Act, could result in material financial impact.
• The potential inability to repatriate earnings from Russia and Ukraine, and difficulties in obtaining licenses for supplying customers in Russia, could impact financial flexibility and business operations in those regions.

Future Outlook

The company expects the 2024 stimulus program in China to create long-term opportunities despite near-term delays impacting orders and revenues. Tariffs are anticipated to continue materially impacting financial results through additional costs. Management believes existing cash, future operating cash flows, access to capital markets, and credit facilities will be sufficient to meet operational needs, debt service, and business investments for at least the next 12 months. Approximately $350 million in cash contributions to postretirement benefit plans are expected in 2025, and an additional $24 million in restructuring expenses are anticipated over the next 12 months. The acquisition of icometrix NV is expected to close in the fourth quarter of 2025.

Management Comments

• We expect the 2024 stimulus program will result in opportunities for our business in China in the longer term, but it has had short-term impacts as provinces develop and announce their plans and customers begin to make purchasing decisions, which has progressed slower than originally anticipated.
• We expect these delays to continue to impact our orders and revenues in the near term, although we are unable to predict the exact duration or magnitude of the impact.
• While we are taking actions to mitigate the impact of tariffs, we do not expect to be able to fully offset the additional costs or other negative impacts resulting from the tariffs.
• We believe that our existing balance of Cash, cash equivalents, and restricted cash, future cash generated from operating activities, access to capital markets, and existing credit facilities will be sufficient to meet the needs of our current and ongoing operations, pay taxes due, service our existing debt, and fund investments in our business for at least the next 12 months.

Industry Context

The healthcare industry is experiencing significant macroeconomic and geopolitical pressures, including global trade tariffs and conflicts, which are increasing costs and impacting supply chains. Despite these challenges, there's a continued focus on innovation in medical technology, pharmaceutical diagnostics, and AI-enabled solutions, as evidenced by GE HealthCare's strategic acquisitions in radiopharmaceuticals (NMP) and neurological care AI (icometrix NV). The China market presents both opportunities, driven by government stimulus programs aimed at expanding healthcare access, and short-term challenges due to slower-than-anticipated program implementation and trade frictions. The company's investment in cloud, edge computing, and AI reflects a broader industry trend towards digital transformation in healthcare.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks. Therefore, a direct comparison to industry standards with specific comparable entities is not possible based on the provided information.

Corporate Governance

Legal Proceedings

• The company is involved in an ongoing legal matter regarding contracts with the Iraqi Ministry of Health, where U.S. Service members, civilians, and their families allege violations of the U.S. Anti-Terrorism Act. The D.C. Circuit's decision is currently pending after the Supreme Court vacated a prior D.C. Circuit decision and remanded the case for further consideration.

Related Party Transactions

• General Electric Company (now GE Aerospace) continues to be considered a related party following the spin-off. Net costs incurred with GE were not significant for the nine months ended September 30, 2025.

Stakeholder Impact

• Shareholders: Experienced a decrease in Q3 net income and EPS, but an increase in YTD net income and EPS. A share repurchase program was authorized, and dividends were declared ($0.07 per common share in Q3).
• Employees: Restructuring activities are ongoing, involving workforce reductions and associated termination benefits.
• Customers: The Patient Care Solutions (PCS) segment experienced a product hold, impacting revenues. Customers in China are affected by slower-than-anticipated implementation of a government stimulus program, influencing purchasing decisions.
• Suppliers: The company participates in voluntary supply chain finance programs. Cost inflation and tariffs are impacting the cost of products and services, which could affect supplier relationships and pricing.
• Creditors: The company issued new senior unsecured notes and repaid existing debt, demonstrating active debt management. Compliance with debt covenants is maintained, providing stability for creditors.

Next Steps

• Closing the acquisition of icometrix NV, which is expected in the fourth quarter of 2025.
• Continuing to evaluate the non-income tax impacts of the One Big Beautiful Bill Act.
• Monitoring global markets for changes in customer behavior, government spending, and reimbursement.
• Applying for licenses to supply customers and support business in Russia, as required by evolving regulations.
• Assessing whether developments related to the Russia-Ukraine conflict have had, or are reasonably likely to have, a material impact on the company.
• Incurring additional restructuring expenses of approximately $24 million, primarily over the next 12 months, related to workforce reductions and asset write-downs.

Key Dates

Recommendation

While GE HealthCare demonstrated positive revenue growth and strategic acquisitions, the decline in Q3 profitability (net income, EPS, operating income) and year-to-date free cash flow raises concerns. Headwinds from cost inflation, tariffs, and delays in the China market stimulus program are impacting financial performance. The mixed results, with some segments performing well and others facing challenges, suggest a cautious stance. A 'Hold' recommendation is appropriate as the company navigates these complex operational and macroeconomic factors, with investors awaiting clearer signs of sustained profitability and cash flow improvement.

Keywords

Healthcare Technology, Medical Devices, Pharmaceutical Diagnostics, Imaging, Patient Care, AI Solutions, SEC Filing, Financial Results, Q3 2025, Earnings, Revenue, Acquisitions, Share Repurchase, Debt, Tariffs, China Market, Supply Chain